Search Results - "Mato, R"

Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia by Shanafelt, Tait D, Wang, Xin V, Kay, Neil E, Hanson, Curtis A, O’Brien, Susan, Barrientos, Jacqueline, Jelinek, Diane F, Braggio, Esteban, Leis, Jose F, Zhang, Cong C, Coutre, Steven E, Barr, Paul M, Cashen, Amanda F, Mato, Anthony R, Singh, Avina K, Mullane, Michael P, Little, Richard F, Erba, Harry, Stone, Richard M, Litzow, Mark, Tallman, Martin

“…Patients 70 years of age or younger with previously untreated CLL were randomly assigned to receive ibrutinib plus rituximab or chemoimmunotherapy with…”
Get full text

Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial by Shanafelt, Tait D, Wang, Xin Victoria, Hanson, Curtis A, Paietta, Elisabeth M, O'Brien, Susan, Barrientos, Jacqueline, Jelinek, Diane F, Braggio, Esteban, Leis, Jose F, Zhang, Cong Christine, Coutre, Steven E, Barr, Paul M, Cashen, Amanda F, Mato, Anthony R, Singh, Avina K, Mullane, Michael P, Little, Richard F, Erba, Harry, Stone, Richard M, Litzow, Mark, Tallman, Martin, Kay, Neil E

“…Herein, we present the long-term follow-up of the randomized E1912 trial comparing the long-term efficacy of ibrutinib-rituximab (IR) therapy to fludarabine,…”
Get full text

Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis by Mato, Anthony R, Nabhan, Chadhi, Thompson, Meghan C, Lamanna, Nicole, Brander, Danielle M, Hill, Brian, Howlett, Christina, Skarbnik, Alan, Cheson, Bruce D, Zent, Clive, Pu, Jeffrey, Kiselev, Pavel, Goy, Andre, Claxton, David, Isaac, Krista, Kennard, Kaitlin H, Timlin, Colleen, Landsburg, Daniel, Winter, Allison, Nasta, Sunita D, Bachow, Spencer H, Schuster, Stephen J, Dorsey, Colleen, Svoboda, Jakub, Barr, Paul, Ujjani, Chaitra S

“…Clinical trials that led to ibrutinib's approval for the treatment of chronic lymphocytic leukemia showed that its side effects differ from those of…”
Get full text

Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study by O'Brien, Susan, Prof, Jones, Jeffrey A, MD, Coutre, Steven E, Prof, Mato, Anthony R, MD, Hillmen, Peter, Prof, Tam, Constantine, MD, Österborg, Anders, Prof, Siddiqi, Tanya, MD, Thirman, Michael J, MD, Furman, Richard R, MD, Ilhan, Osman, Prof, Keating, Michael J, Prof, Call, Timothy G, MD, Brown, Jennifer R, MD, Stevens-Brogan, Michelle, MSc, Li, Yunfeng, PhD, Clow, Fong, ScD, James, Danelle F, MD, Chu, Alvina D, MD, Hallek, Michael, Prof, Stilgenbauer, Stephan, Prof

“…Summary Background The TP53 gene, encoding tumour suppressor protein p53, is located on the short arm of chromosome 17 (17p). Patients with 17p deletion…”
Get full text

Novel-agent combination therapies in chronic lymphocytic leukemia: the law of relative contributions by Mato, Anthony R, Roeker, Lindsey E

Get full text

A clinical practice comparison of patients with chronic lymphocytic leukemia with and without deletion 17p receiving first-line treatment with ibrutinib by Mato, Anthony R, Tang, Boxiong, Azmi, Soraya, Yang, Keri, Zhang, Xiaojuan, Stern, Jennifer C, Hedrick, Eric, Huang, Jane, Sharman, Jeff P

“…Among patients with chronic lymphocytic leukemia (CLL) with deletion 17p (del[17p]), evidence from clinical trials for the effectiveness of single-agent…”
Get full text

All in the family: back-to-back kinase inhibitors for the treatment of chronic lymphocytic Leukemia by Thompson, Meghan C, Roeker, Lindsey E, Mato, Anthony R

Get full text

The impact of early discontinuation/dose modification of venetoclax on outcomes in patients with relapsed/refractory chronic lymphocytic leukemia: post-hoc analyses from the phase III MURANO study by Mato, Anthony R, Sharman, Jeff P, Biondo, Juliana M L, Wu, Mei, Mun, Yong, Kim, Su Y, Humphrey, Kathryn, Boyer, Michelle, Zhu, Qian, Seymour, John F

“…Fixed-duration venetoclax plus rituximab (VenR) has a manageable safety profile and improves survival in patients with relapsed/refractory (R/R) chronic…”
Get full text

Utility of positron emission tomography-computed tomography in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapy by Mato, Anthony R, Wierda, William G, Davids, Matthew S, Cheson, Bruce D, Coutre, Steven E, Choi, Michael, Furman, Richard R, Heffner, Leonard, Barr, Paul M, Eradat, Herbert, Ford, Sharanya M, Zhou, Lang, Verdugo, Maria, Humerickhouse, Rod A, Potluri, Jalaja, Byrd, John C

“…The utility of positron emission tomography-computed tomography (PET-CT) in distinguishing Richter's transformation chronic lymphocytic leukemia (CLL)…”
Get full text

Acalabrutinib and Its Therapeutic Potential in the Treatment of Chronic Lymphocytic Leukemia: A Short Review on Emerging Data by Isaac, Krista, Mato, Anthony R

“…Recently, the treatment landscape for chronic lymphocytic leukemia (CLL) has changed dramatically due to the development of drugs targeting proteins in the B…”
Get full text

A predictive approach in modeling and simulation of heat and mass transfer during microwave heating. Application to SFME of essential oil of Lavandin Super by Navarrete, A., Mato, R.B., Cocero, M.J.

“…Solvent Free Microwave Extraction (SFME) is a new and faster process with higher energy efficiency used to extract essential oils. Nevertheless, so far no…”
Get full text

Real-World Evidence for Chronic Lymphocytic Leukemia in the Era of Targeted Therapies by Islam, Prioty, Mato, Anthony R

“…The landscape of chronic lymphocytic leukemia has transformed in the era of small molecule inhibitor targeted therapies. While randomized controlled trials…”
Get full text

COVID‐19 Vaccination Response and Its Practical Application in Patients With Chronic Lymphocytic Leukemia by Shadman, Mazyar, Liu, Catherine, Eakle, Katherine, Hiew, Hwai J., Biondo, Juliana M.L., Ghia, Paolo, Mato, Anthony R.

“…Patients with chronic lymphocyticleukemia (CLL) typically have innate/adaptive immune system dysregulation, thus the protective effect of coronavirus disease…”
Get full text

The potential of pirtobrutinib in multiple B-cell malignancies by Jensen, Jeffrey L., Mato, Anthony R., Pena, Camila, Roeker, Lindsey E., Coombs, Catherine C.

“…Bruton’s tyrosine kinase (BTK) is a critical downstream signaling element from the B-cell receptor (BCR) that has been effectively inhibited in B-cell cancers…”
Get full text

Zanubrutinib (BGB-3111), a Second-Generation Selective Covalent Inhibitor of Bruton's Tyrosine Kinase and Its Utility in Treating Chronic Lymphocytic Leukemia by Rhodes, Joanna M, Mato, Anthony R

“…The understanding of the B cell receptor (BCR) pathway and its contribution to chronic lymphocytic leukemia (CLL) pathogenesis have led to the development of…”
Get full text

Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first‐relapse/primary refractory diffuse large B‐cell lymphoma by Feldman, Tatyana, Mato, Anthony R., Chow, Kar F., Protomastro, Ewelina A., Yannotti, Kara M. L., Bhattacharyya, Pritish, Yang, Xiao, Donato, Michele L., Rowley, Scott D., Carini, Carolanne, Valentinetti, Marisa, Smith, Judith, Gadaleta, Gabriella, Bejot, Coleen, Stives, Susan, Timberg, Mary, Kdiry, Sabrina, Pecora, Andrew L., Beaven, Anne W., Goy, Andre

“…Summary Relapsed/refractory diffuse large B‐cell lymphoma (DLBCL) is associated with a poor prognosis. Outcomes are particularly poor following…”
Get full text

Concrete block production from construction and demolition waste in Tanzania by Sabai, M.M., Cox, M.G.D.M., Mato, R.R., Egmond, E.L.C., Lichtenberg, J.J.N.

“…► Construction and demolition waste was recycled into building materials in Tanzania. ► Eight samples of masonry rubble were recycled in to concrete blocks. ►…”
Get full text

PET/Computed Tomography in Chronic Lymphocytic Leukemia and Richter Transformation by Rhodes, Joanna M., MD, Mato, Anthony R., MD, MSCE

“…Chronic lymphocytic leukemia (CLL) is the most common leukemia in the United States. In 1-10% of cases, it can undergo Richter's transformation (RT) to either…”
Get full text

Reduced‐dose fludarabine, cyclophosphamide, and rituximab (FCR‐Lite) plus lenalidomide, followed by lenalidomide consolidation/maintenance, in previously untreated chronic lymphocytic leukemia by Mato, Anthony R., Foon, Kenneth A., Feldman, Tatyana, Schuster, Stephen J., Svoboda, Jakub, Chow, Kar Fai, Valentinetti, Marisa, Mrkulic, Mary, Azzollini, Kelly, Gadaleta, Gabriella, Bhattacharyya, Pritish K., Zenreich, Joshua, Pascual, Lauren‐Nicole, Yannotti, Kara, Kdiry, Sabrina, Howlett, Christina, Strelec, Lauren, Porter, David, Bejot, Coleen, Goy, André

“…Fludarabine, cyclophosphamide, and rituximab (FCR) remains the standard of care for fit chronic lymphocytic leukemia (CLL) patients requiring first therapy…”
Get full text

Multicenter Analysis of Advanced Stage Grade 3A Follicular Lymphoma Outcomes by Frontline Treatment Regimen by Shah, Nirav N., Szabo, Aniko, Saba, Raya, Strelec, Lauren, Kodali, Dheeraj, Vaughn, John L., Esan, Olukemi, Yang, David T., Mato, Anthony R., Kanate, Abraham S., Olteanu, Horatiu, Hamadani, Mehdi, Fenske, Timothy S., Kenkre, Vaishalee P., Svoboda, Jakub, Cashen, Amanda F., Epperla, Narendranath

“…Grade 3A follicular lymphoma (FL) is a heterogenous disease with multiple frontline treatment regimens. We performed a multicenter retrospective analysis to…”
Get full text